Precigen (NASDAQ:PGEN) CFO Harry Jr. Thomasian Sells 100,000 Shares

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 100,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.06, for a total value of $606,000.00. Following the sale, the chief financial officer directly owned 254,535 shares in the company, valued at $1,542,482.10. This represents a 28.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The shares were sold at an average price of $5.53, for a total value of $948,002.37.
• On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The shares were sold at an average price of $5.78, for a total value of $165,140.38.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The stock was sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $6.27 on Friday. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -5.31 and a beta of 1.00. The stock’s 50-day moving average is $4.98 and its two-hundred day moving average is $4.41. Precigen, Inc. has a 1-year low of $1.63 and a 1-year high of $6.28.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business had revenue of $23.25 million during the quarter, compared to analysts’ expectations of $20.81 million. Analysts forecast that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PGEN. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. HC Wainwright increased their price objective on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Citizens Jmp lifted their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $12.50.

Institutional Investors Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in the business. Occam Crest Management LP raised its holdings in Precigen by 29.6% during the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after purchasing an additional 799,339 shares in the last quarter. KBC Group NV purchased a new stake in shares of Precigen during the 1st quarter worth approximately $1,338,000. UBS Group AG boosted its holdings in shares of Precigen by 41.4% in the 4th quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock valued at $3,726,000 after buying an additional 260,824 shares in the last quarter. Investment Insight Wealth Management LLC acquired a new position in shares of Precigen in the 4th quarter valued at $443,000. Finally, Impala Asset Management LLC acquired a new position in shares of Precigen in the 4th quarter valued at $690,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.